NCT01352208View on ClinicalTrials.gov

Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Castrate Resistant Prostate Cancer
Interventions
DRUG

ASP9521

oral

Trial Locations (4)

2650

Site 131, Antwerp

Unknown

Site: 121, Villejuif

Site:109, Glasgow

Site: 101, Surrey

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY